Also trades as: BIO (NYSE) · $vol 107M

$379.50

+15.35 (+4.22%)

Weekly Expected Move ±0.3%

$364 $365 $366 $367 $368

NYSE · Healthcare · Medical - Devices · Tech Score Buy · Power 69 · $9.9B mcap · 522410 float · 0.017% daily turnover

Credit Risk of going bust: lower than 70% of companies Debt: 10.6% of company value Bonds: none of note held by US funds details ▾

Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $4.62 (down 99%), Bio-Rad Laboratories, Inc. would be worth roughly what it owes.
Total debt $1.20B against a stock market value of $10.19B.
Distance to default 7.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $802.2M (short-term plus half of long-term), stock volatility 36.7%; Altman Z 3.86. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Overview News Chart Smart Money Financials Income Statement Cash Flow Balance Sheet Earnings

Dividends Analysis Technicals Weather Peers ESG Institutions Dark Pool Short Interest Supply Chain

Analyst Insights

Wall Street analyst consensus based on price targets and buy/sell/hold recommendations from institutional research coverage over the trailing 12 months.

Analyst Price Targets

Analyst Recommendations

Strong Buy: 1Buy: 8Hold: 2Sell: 0Strong Sell: 0

Rating Summary

ConsensusBuy

Avg Target$—

Analysts0

Financial Rating

Composite financial health rating (A+ to F) based on discounted cash flow valuation, return on equity, return on assets, debt-to-equity leverage, and relative P/E and P/B multiples.

B-

Oct 27, 2026

DCF

ROE

ROA

D/E

P/E

P/B

The Financial Rating evaluates six fundamental factors — discounted cash flow (DCF) valuation, return on equity (ROE), return on assets (ROA), debt-to-equity leverage (D/E), and relative price-to-earnings (P/E) and price-to-book (P/B) multiples — each scored 1–5. BIO-B receives an overall rating of B-. Strongest factors: P/B (4/5). Areas of concern: ROE (2/5), ROA (1/5), P/E (2/5).

Rating Change History

Date	From	To
2026-10-13	None	ADDED
2026-10-12	EXISTED	None
2026-10-01	B-	C+
2026-09-30	None	ADDED
2026-09-30	EXISTED	None
2026-09-15	None	ADDED
2026-09-13	EXISTED	None
2026-09-09	None	ADDED
2026-09-07	EXISTED	None
2026-07-27	B	B-

InsiderStreet Scorecard

Proprietary multi-factor scorecard rating companies across seven fundamental dimensions — profitability, balance sheet strength, earnings quality, growth, value, momentum, and safety — each scored 0–100.

★ ★ ★ ★ ★ 55 Grade A

Profitability

Balance Sheet

Earnings Quality

Growth

Value

Momentum

Safety

Cash Flow

The InsiderStreet Scorecard rates companies across eight dimensions: Profitability (margins, ROA, ROE), Balance Sheet (leverage, liquidity, coverage), Earnings Quality (accruals, cash conversion), Growth (revenue and earnings trajectory), Value (P/E, P/B, earnings yield, Graham criteria), Momentum (revenue and earnings acceleration), Safety (Altman Z-Score risk adjustment), and Cash Flow (operating cash flow quality, FCF conversion, cash coverage). The overall score blends 35% quality, 35% value, and 30% momentum, with a penalty for distress-zone Altman scores. BIO-B scores highest in Balance Sheet (93/100) and lowest in Growth (21/100). An overall grade of A places BIO-B among the highest-quality companies in its peer group.

Risk & Quality Signals

Academic financial models used by institutional investors to assess bankruptcy risk, earnings manipulation, financial strength, and credit quality.

Altman Z-Score

3.42

Safe Zone

Piotroski F-Score

7/9

✓ ✓ ✗ ✓ ✓ ✗ ✓ ✓ ✓

Beneish M-Score

-2.67

Unlikely Manipulator

Ohlson O-Score

-9.41

Bankruptcy prob: 0.0%

Low Risk

Credit Rating

AA+

Score: 90.1/100

Trend: Improving

Earnings Quality

100/100

OCF/NI: 2.21x

Accruals: -2.6%

The Altman Z-Score (1968) combines five ratios — working capital, retained earnings, EBIT, market value of equity, and sales, all relative to total assets or liabilities — into a single bankruptcy predictor. BIO-B scores 3.42, placing it in the Safe Zone (safe > 2.99, distress < 1.81). Bankruptcy is statistically unlikely within the next two years. The Piotroski F-Score (2000) is a 9-point binary checklist — four profitability tests (positive ROA, positive cash flow, improving ROA, cash flow exceeding net income), three leverage tests (declining debt ratio, improving current ratio, no share dilution), and two efficiency tests (improving gross margin, improving asset turnover). Each pass scores 1 point. BIO-B scores 7/9, signaling strong financial health across all three dimensions. The Beneish M-Score (1999) is an 8-variable model that detects earnings manipulation by comparing year-over-year changes in receivables, gross margins, asset quality, sales growth, depreciation, SG&A, leverage, and accruals. Scores above −1.78 statistically resemble past manipulators. BIO-B's score of -2.67 falls below this threshold, suggesting earnings are unlikely to be manipulated. The Ohlson O-Score (1980) is a 9-variable logistic regression that estimates bankruptcy probability using firm size, leverage, working capital, current ratio, profitability (ROA), cash flow coverage, negative equity flag, consecutive losses flag, and earnings trajectory. The raw score is converted to a probability via logistic transformation. BIO-B's implied 0.0% bankruptcy probability is well within safe territory. Our Credit Rating model scores companies on five weighted components — solvency (30%), earning power (25%), leverage (20%), liquidity (15%), and cash flow quality (10%) — then blends the absolute score with sector and industry peer rankings. For companies with large buyback programs, equity is adjusted by adding back cumulative 5-year repurchases (capped at 80% of FCF generated) to avoid penalizing shareholder-friendly capital allocation. BIO-B receives an estimated rating of AA+ (score: 90.1/100), with a improving trend. The Earnings Quality score measures how well reported earnings are backed by real cash. It evaluates the operating cash flow to net income ratio (OCF/NI ≥ 1.0 means every dollar of earnings is cash-backed) and the accruals ratio (the gap between earnings and cash flow relative to assets — lower is better). BIO-B's score of 100/100 is high — cash flows strongly support reported earnings.

Valuation

Key valuation multiples comparing the stock's market price to its earnings, revenue, book value, and cash flows. Lower multiples may indicate relative undervaluation versus peers.

P/E

45.74x

PEG

-0.16x

P/S

3.93x

P/B

1.42x

P/FCF

22.52x

P/OCF

16.14x

EV/EBITDA

7.39x

EV/Revenue

2.91x

EV/EBIT

8.64x

EV/FCF

21.34x

Earnings Yield

2.80%

FCF Yield

4.44%

Shareholder Yield

2.29%

Graham Number

$223.45

Equity-based multiples (P/E, P/B, P/FCF) compare the stock price to per-share fundamentals and are affected by capital structure. Enterprise value multiples (EV/EBITDA, EV/Revenue, EV/FCF) strip out debt and cash, making them more useful for cross-company comparisons regardless of how companies are financed. The Graham Number — √(22.5 × EPS × Book Value) — is Benjamin Graham's formula for the maximum price a defensive investor should pay. At 45.7x earnings, BIO-B is priced for high growth expectations. Graham's intrinsic value formula yields $223.45 per share, 70% below the current price.

DuPont Decomposition (5-Factor)

The 5-factor DuPont framework breaks Return on Equity into its component drivers — tax efficiency, interest burden, operating profitability, asset utilization, and financial leverage — to reveal what truly drives shareholder returns.

Tax Burden

0.635

NI / EBT

Interest Burden

0.402

EBT / EBIT

EBIT Margin

0.337

EBIT / Rev

Asset Turnover

0.253

Rev / Assets

Equity Multiplier

1.431

Assets / Equity

ROE

3.1%

The 5-factor DuPont identity decomposes ROE as: Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Equity Multiplier = ROE. This reveals whether returns are driven by operating performance, financial leverage, or tax efficiency — three very different sources of profitability. BIO-B's ROE of 3.1% is driven by a balanced combination of operating margin, asset efficiency, and leverage.

Graham-Dodd Adjusted Valuation

Our adaptation of Graham's growth formula (Fair P/E = 8.5 + 2g) from The Intelligent Investor. The classic version relies on analyst growth projections, which can be unreliable. This adjusted model substitutes the company's realized 3-year EPS CAGR — a backward-looking, verifiable measure of actual earnings power — grounding the valuation in demonstrated performance rather than forecasts.

Two adjustments we make, and why. Growth is capped at 15%. Graham defined g as expected growth over the next seven to ten years, not last year's rate. Across US companies since 1994 the median realized 7-year EPS growth is 5–8% regardless of how fast a company grew beforehand, and of 4,457 company-quarters that grew faster than 200%, none sustained it. Uncapped, the formula assigned fair multiples in the hundreds to companies that had never held that rate — and scored worse than simply reading the P/E. Capped, it carries real information. The verdict has three states, not two. Tested over 377,249 stock-months, this ratio only separates outcomes at its extremes: below 0.25 beat the universe by 1.3 points a year, above 3.0 lagged by 2.7, and everything in between sat inside a one-point band. Rather than call two-thirds of the market "undervalued" on a threshold of 1.0, we say Neutral where the model cannot tell — which is most of the time.

Adj. Growth Rate

0.00%

Fair P/E

8.50x

Intrinsic Value

$70.50

Price/Value

4.21x

Margin of Safety

-320.55%

Premium

320.55%

Assessment

Overvalued

Graham's classic formula uses analyst-projected growth to estimate a fair P/E (8.5 + 2g). Our adjusted version replaces that projection with BIO-B's realized 0.0% 3-year EPS CAGR, capped at 15% — demonstrated performance rather than forecasts, held to a rate companies have historically sustained. BIO-B trades at a 321% premium to its adjusted intrinsic value of $70.50, suggesting the market is pricing in future growth beyond what historical earnings support. The adjusted fair P/E of 8.5x compares to the current market P/E of 45.7x.

Profitability Trends

Historical profitability ratios tracking how efficiently the company converts revenue into returns for shareholders over time.

Leverage & Solvency Trends

Debt and liquidity metrics showing the company's financial leverage and ability to meet short-term and long-term obligations.

Efficiency & Working Capital Trends

Operating efficiency metrics measuring how quickly the company converts inventory to sales, collects receivables, and manages its cash conversion cycle.

Growth Trends (YoY %)

Year-over-year growth rates for key financial metrics, showing the trajectory of revenue, earnings, and cash flow generation.

Earnings Stability

R-squared of linear regression measuring how predictably revenue, earnings, and margins follow a trend over the trailing 5 years. 1.0 = perfectly predictable; lower values indicate erratic or cyclical behavior.

Monte Carlo Price Simulation

Geometric Brownian Motion with 1,000 antithetic paths over 1 year, seeded from 1800 days of historical volatility. Percentile bands show the range of statistically plausible outcomes — this is a statistical model, not a forecast.

Current Price

$379.50

Median 1Y

$382.57

5th Pctile

$207.27

95th Pctile

$707.76

Ann. Volatility

34.4%

25th–75th percentile 5th–95th percentile Median path Historical

Executive Compensation

C-suite compensation breakdown including salary, stock awards, options, and incentive pay. The CEO-to-employee pay ratio and Gini coefficient measure pay distribution fairness.

C-Suite Compensation

Executive	Salary	Stock	Total
Norman Schwartz Chief Executive Officer and Chairman	$1,089,877	$4,856,574	$7,995,841
Jonathan P. DiVincenzo President and Chief Operating Officer	$673,208	$2,023,696	$3,680,772
Roop K. Lakkaraju Executive Vice President, Chief Financial Officer	$629,100	$1,618,956	$2,990,738
Rajat Mehta President, Vice President, Global Commercial Operations	$220,096	$2,158,707	$2,680,042
James Barry President, Vice President, President, Life Science Group	$536,752	$1,214,217	$2,611,227

CEO Pay Ratio

73:1

CEO-to-Employee Pay Ratio

CEO Total Comp: $7,995,841

Avg Employee Cost (SGA/emp): $110,054

Employees: 7,450

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Workforce efficiency metrics measuring revenue, profit, and R&D spend per employee — key indicators of operational leverage and human capital productivity.

Employees

7,450

-3.2% YoY

Revenue / Employee

$346,738

Rev: $2,583,200,000

Profit / Employee

$102,000

NI: $759,900,000

SGA / Employee

$110,054

Avg labor cost proxy

R&D / Employee

$34,483

Innovation spend

Scaling Efficiency

All Ratios & Metrics

Complete fundamental data with up to 20 periods of history, sparkline trends, and current values across 13 categories and 130+ financial metrics.

Profitability

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
ROE	55.1%	36.0%	-1.0%	-18.9%	-50.7%	-31.1%	-1.9%	-4.9%	-1.8%	-6.9%	-3.4%	-17.4%	-9.8%	-24.1%	-27.5%	4.6%	-9.5%	10.8%	2.5%	3.1%	3.11%
ROA	41.7%	27.6%	-0.7%	-14.0%	-37.7%	-23.2%	-1.3%	-3.4%	-1.3%	-4.9%	-2.5%	-12.2%	-6.9%	-17.0%	-19.6%	3.2%	-6.7%	7.6%	1.7%	2.2%	2.17%
ROIC	3.1%	2.9%	4.4%	5.0%	4.6%	4.1%	3.3%	3.5%	3.5%	3.1%	3.0%	4.1%	3.4%	3.5%	3.1%	2.2%	2.7%	2.3%	2.7%	2.2%	2.21%
ROCE	44.3%	31.8%	-1.6%	-21.4%	-68.0%	-36.1%	-1.6%	-4.2%	-1.2%	-6.8%	-3.2%	-18.3%	-9.5%	-25.8%	-29.9%	5.2%	-3.4%	15.2%	8.5%	9.4%	9.39%
Gross Margin	58.6%	54.7%	57.5%	57.3%	54.9%	54.4%	53.5%	53.2%	53.1%	53.7%	53.4%	55.6%	54.8%	51.2%	52.3%	53.0%	52.6%	49.8%	52.3%	53.1%	53.12%
Operating Margin	21.0%	14.6%	20.9%	17.4%	13.6%	16.2%	9.1%	13.2%	14.4%	14.4%	8.5%	15.9%	9.9%	8.7%	4.0%	11.8%	10.2%	8.9%	5.8%	11.2%	11.15%
Net Margin	5.3%	-2.1%	-4.8%	-1.3%	-24.1%	1.1%	10.2%	-1.7%	16.8%	51.3%	62.9%	-3.4%	1.0%	-1.1%	10.9%	48.8%	-52.4%	1.0%	-89.0%	57.1%	57.05%
EBITDA Margin	6.8%	-2.7%	-6.2%	-1.7%	-23.7%	1.6%	21.1%	-2.1%	31.3%	72.5%	90.2%	-4.3%	1.4%	-1.3%	22.8%	73.2%	18.5%	1.4%	-1.1%	83.3%	83.27%
FCF Margin	22.4%	18.3%	15.9%	12.7%	5.4%	2.9%	4.5%	5.5%	8.2%	8.2%	7.1%	6.9%	8.7%	10.4%	13.1%	13.6%	13.2%	14.5%	13.8%	13.6%	13.64%
OCF Margin	26.3%	22.5%	20.5%	17.1%	9.7%	7.3%	9.1%	10.7%	14.1%	14.0%	13.3%	13.5%	16.0%	17.7%	20.3%	20.9%	19.2%	20.6%	19.7%	19.0%	19.02%
ROE 3Y Avg	snapshot only																				-3.99%
ROE 5Y Avg	snapshot only																				-7.75%
ROA 3Y Avg	snapshot only																				-2.80%
ROIC 3Y Avg	snapshot only																				-3.50%
ROIC Economic	snapshot only																				1.79%
Cash ROA	snapshot only																				4.80%
Cash ROIC	snapshot only																				7.29%
CROIC	snapshot only																				5.22%
NOPAT Margin	snapshot only																				5.76%
Pretax Margin	snapshot only																				13.53%
R&D / Revenue	snapshot only																				10.08%
SGA / Revenue	snapshot only																				32.74%
SBC / Revenue	snapshot only																				0.58%

Valuation

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
P/E Ratio	3.45	5.09	-177.90	-7.24	-2.06	-3.33	-73.06	-25.69	-67.58	-14.50	-29.41	-6.07	-11.74	-4.94	-3.13	21.33	-11.35	11.04	44.44	35.75	45.737
P/S Ratio	7.71	7.40	6.07	4.89	4.44	4.30	4.97	3.93	3.81	3.46	3.64	3.14	3.54	3.55	2.66	2.67	3.00	3.25	2.90	3.07	3.934
P/B Ratio	1.50	1.58	1.73	1.57	1.47	1.25	1.41	1.29	1.23	1.06	1.05	1.19	1.22	1.39	1.01	0.96	1.14	1.13	1.09	1.11	1.420
P/FCF	34.45	40.38	38.31	38.63	82.17	150.15	110.21	71.31	46.54	42.33	51.11	45.36	40.87	34.24	20.37	19.59	22.78	22.40	21.00	22.52	22.515
P/OCF	29.32	32.95	29.64	28.56	45.64	58.75	54.60	36.60	27.00	24.64	27.35	23.25	22.19	20.03	13.13	12.75	15.61	15.77	14.70	16.14	16.139
EV/EBITDA	2.51	3.75	-249.22	-5.53	-1.56	-2.58	-379.78	-35.65	159.30	-15.16	-49.12	-5.27	-11.73	-4.20	-2.57	9.97	-65.84	4.86	7.66	7.39	7.389
EV/Revenue	7.34	7.18	5.84	4.69	4.27	4.16	4.80	3.81	3.68	3.38	3.54	3.05	3.45	3.44	2.55	2.68	2.99	3.24	2.82	2.91	2.910
EV/EBIT	2.55	3.86	-76.25	-5.21	-1.53	-2.50	-65.05	-21.82	-72.39	-11.29	-23.41	-4.66	-9.32	-3.85	-2.40	13.71	-24.80	5.48	9.67	8.64	8.638
EV/FCF	32.80	39.17	36.85	37.04	79.06	145.14	106.46	69.08	44.95	41.41	49.78	44.10	39.82	33.16	19.49	19.69	22.70	22.37	20.48	21.34	21.340
Earnings Yield	29.0%	19.6%	-0.6%	-13.8%	-48.5%	-30.1%	-1.4%	-3.9%	-1.5%	-6.9%	-3.4%	-16.5%	-8.5%	-20.2%	-32.0%	4.7%	-8.8%	9.1%	2.3%	2.8%	2.80%
FCF Yield	2.9%	2.5%	2.6%	2.6%	1.2%	0.7%	0.9%	1.4%	2.1%	2.4%	2.0%	2.2%	2.4%	2.9%	4.9%	5.1%	4.4%	4.5%	4.8%	4.4%	4.44%
Price/Tangible Book	snapshot only																				1.235
EV/OCF	snapshot only																				15.297
EV/Gross Profit	snapshot only																				5.607
Acquirers Multiple	snapshot only																				32.065
Shareholder Yield	snapshot only																				2.29%
Graham Number	snapshot only																				$223.45

Leverage & Solvency

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Current Ratio	3.79	2.92	5.10	5.30	5.50	5.55	5.56	5.39	5.64	5.83	6.57	6.28	6.14	6.48	5.99	5.12	5.44	5.62	3.21	3.14	3.142
Quick Ratio	2.89	2.08	4.16	4.22	4.30	4.29	4.28	4.06	4.25	4.34	4.89	4.63	4.52	4.85	4.43	3.67	3.94	4.19	2.37	2.33	2.330
Debt/Equity	0.02	0.02	0.14	0.16	0.16	0.14	0.14	0.16	0.17	0.16	0.15	0.21	0.19	0.21	0.21	0.20	0.21	0.21	0.20	0.17	0.168
Net Debt/Equity	-0.07	-0.05	-0.07	-0.06	-0.06	-0.04	-0.05	-0.04	-0.04	-0.02	-0.03	-0.03	-0.03	-0.04	-0.04	0.00	-0.00	-0.00	-0.03	-0.06	-0.058
Debt/Assets	0.01	0.01	0.10	0.11	0.11	0.10	0.10	0.12	0.12	0.11	0.11	0.14	0.13	0.15	0.14	0.14	0.14	0.14	0.14	0.12	0.117
Debt/EBITDA	0.03	0.04	-20.68	-0.57	-0.18	-0.31	-39.35	-4.67	22.34	-2.36	-7.45	-0.94	-1.83	-0.65	-0.54	2.05	-12.02	0.89	1.44	1.18	1.180
Net Debt/EBITDA	-0.13	-0.12	9.86	0.24	0.06	0.09	13.38	1.15	-5.62	0.34	1.31	0.15	0.31	0.14	0.12	0.05	0.22	-0.01	-0.20	-0.41	-0.407
Interest Coverage	1453.42	3507.22	-42.66	-166.38	-291.35	-122.43	-4.42	-10.07	-2.84	-16.20	-7.99	-34.09	-19.48	-46.90	-55.56	10.19	-6.28	31.22	15.35	23.77	23.768
Equity Multiplier	1.30	1.30	1.41	1.42	1.43	1.40	1.40	1.42	1.41	1.41	1.39	1.43	1.42	1.43	1.43	1.43	1.44	1.42	1.43	1.43	1.429
Cash Ratio	snapshot only																				1.684
Debt Service Coverage	snapshot only																				27.787
Cash to Debt	snapshot only																				1.345
FCF to Debt	snapshot only																				0.293
Defensive Interval	snapshot only																				678.2 days

Efficiency & Turnover

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Asset Turnover	0.19	0.19	0.20	0.21	0.18	0.18	0.20	0.22	0.23	0.21	0.20	0.24	0.23	0.24	0.23	0.26	0.25	0.26	0.27	0.25	0.253
Inventory Turnover	2.08	2.15	2.07	1.96	1.93	1.91	1.84	1.78	1.73	1.66	1.58	1.49	1.49	1.54	1.50	1.50	1.54	1.66	1.60	1.58	1.577
Receivables Turnover	7.27	6.93	6.64	6.76	6.60	6.10	5.78	5.88	6.12	5.43	5.52	5.47	5.61	5.45	5.84	5.58	5.52	5.66	6.09	5.68	5.680
Payables Turnover	9.50	9.11	8.38	8.46	8.82	8.90	7.77	8.27	9.92	8.90	9.21	8.54	10.06	8.90	9.82	9.06	9.73	9.89	9.20	8.81	8.808
DSO	50	53	55	54	55	60	63	62	60	67	66	67	65	67	62	65	66	65	60	64	64.3 days
DIO	175	170	176	186	189	191	198	206	211	220	231	245	245	237	243	243	237	220	228	231	231.4 days
DPO	38	40	44	43	41	41	47	44	37	41	40	43	36	41	37	40	38	37	40	41	41.4 days
Cash Conversion Cycle	187	183	188	197	203	210	215	223	234	246	257	269	274	263	268	268	266	248	249	254	254.2 days
Fixed Asset Turnover	snapshot only																				3.854
Operating Cycle	snapshot only																				295.7 days
Cash Velocity	snapshot only																				1.600
Capital Intensity	snapshot only																				3.959

Growth (YoY)

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue	25.2%	14.8%	7.2%	-0.3%	-5.9%	-4.1%	-4.0%	-3.6%	-3.0%	-4.7%	-6.3%	-7.5%	-5.2%	-3.9%	-2.5%	-0.3%	-0.9%	0.7%	1.9%	1.4%	1.37%
Net Income	89.1%	11.6%	-1.0%	-1.5%	-1.9%	-1.9%	-91.1%	78.1%	97.5%	82.4%	-70.6%	-2.1%	-4.1%	-1.9%	-5.7%	1.2%	13.2%	1.4%	1.1%	-30.3%	-30.32%
EPS	88.5%	12.5%	-1.0%	-1.5%	-1.9%	-1.9%	-92.3%	77.8%	97.4%	81.8%	-77.8%	-2.2%	-4.3%	-2.0%	-5.9%	1.3%	9.8%	1.4%	1.1%	-29.2%	-29.24%
FCF	80.7%	12.4%	-13.3%	-38.0%	-77.3%	-85.0%	-72.7%	-58.0%	47.2%	1.7%	48.1%	16.1%	0.4%	22.0%	79.0%	95.9%	50.5%	40.7%	7.6%	1.6%	1.61%
EBITDA	87.4%	10.6%	-1.0%	-1.5%	-1.9%	-1.8%	48.3%	87.9%	1.0%	86.8%	-4.4%	-4.0%	-13.1%	-2.5%	-12.4%	1.5%	84.7%	1.8%	1.4%	48.6%	48.62%
Op. Income	89.1%	19.1%	22.3%	3.9%	-16.4%	-2.3%	-26.4%	-31.6%	-22.6%	-28.8%	-16.1%	-5.7%	-12.6%	-18.8%	-24.9%	-34.7%	-28.6%	-17.1%	-3.4%	5.1%	5.10%
OCF Growth	snapshot only																				-7.78%
Asset Growth	snapshot only																				0.37%
Equity Growth	snapshot only																				0.63%
Debt Growth	snapshot only																				-14.42%
Shares Change	snapshot only																				-1.52%

Growth (CAGR)

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue 3Y	9.1%	8.5%	8.1%	7.8%	6.8%	6.6%	6.1%	6.5%	4.6%	1.6%	-1.2%	-3.8%	-4.7%	-4.2%	-4.3%	-3.8%	-3.0%	-2.7%	-2.3%	-2.2%	-2.21%
Revenue 5Y	7.6%	7.2%	6.7%	6.6%	5.8%	5.3%	4.7%	3.9%	3.5%	3.1%	2.6%	2.3%	2.3%	2.1%	1.8%	2.2%	1.4%	0.3%	-0.8%	-2.1%	-2.10%
EPS 3Y	74.1%	1.3%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
EPS 5Y	1.3%	1.7%	—	—	—	—	—	—	—	—	—	—	—	—	—	-29.0%	—	-25.9%	-46.0%	-42.7%	-42.69%
Net Income 3Y	74.0%	1.3%	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Net Income 5Y	1.3%	1.7%	—	—	—	—	—	—	—	—	—	—	—	—	—	-30.3%	—	-27.5%	-47.2%	-44.0%	-44.02%
EBITDA 3Y	70.5%	1.0%	—	—	—	—	—	—	-76.2%	—	—	—	—	—	—	—	—	—	—	—	—
EBITDA 5Y	97.4%	93.5%	—	—	—	—	—	—	-48.6%	—	—	—	—	—	—	-23.7%	—	-19.4%	-29.5%	-28.3%	-28.31%
Gross Profit 3Y	11.4%	10.2%	10.0%	9.7%	7.7%	7.7%	6.6%	6.2%	3.7%	-0.3%	-2.9%	-5.3%	-6.2%	-5.6%	-6.1%	-6.2%	-5.3%	-5.1%	-4.2%	-3.5%	-3.51%
Gross Profit 5Y	8.5%	7.6%	7.5%	7.6%	6.2%	5.7%	4.6%	3.7%	3.5%	3.1%	2.4%	2.2%	2.2%	1.9%	1.5%	1.6%	0.4%	-1.4%	-2.5%	-3.8%	-3.78%
Op. Income 3Y	48.4%	—	—	—	—	27.7%	16.7%	14.3%	7.0%	-6.1%	-8.9%	-12.5%	-17.3%	-17.4%	-22.6%	-25.0%	-21.5%	-21.7%	-15.3%	-13.5%	-13.49%
Op. Income 5Y	32.6%	55.9%	58.8%	79.9%	58.6%	32.6%	23.9%	14.9%	16.2%	—	—	—	—	3.8%	0.0%	-1.6%	-5.2%	-11.0%	-11.4%	-14.4%	-14.37%
FCF 3Y	65.2%	51.0%	41.6%	14.3%	-17.8%	-39.3%	-31.0%	-22.0%	-15.5%	-22.9%	-29.5%	-32.9%	-30.5%	-20.8%	-10.2%	-1.5%	30.5%	67.1%	41.8%	32.2%	32.22%
FCF 5Y	82.5%	48.2%	1.1%	—	—	—	5.1%	5.7%	8.6%	7.0%	2.8%	-6.2%	-3.9%	-5.8%	-2.7%	1.5%	-1.8%	-4.7%	-7.6%	-9.7%	-9.65%
OCF 3Y	46.4%	32.0%	27.2%	10.4%	-12.2%	-23.5%	-19.1%	-10.5%	-5.2%	-13.3%	-17.9%	-20.5%	-19.3%	-11.5%	-4.6%	2.8%	21.7%	37.4%	26.4%	18.3%	18.29%
OCF 5Y	37.9%	24.8%	28.8%	26.3%	16.0%	14.5%	4.7%	6.6%	9.0%	5.6%	3.8%	-1.1%	0.4%	-0.1%	1.5%	5.2%	1.8%	-1.5%	-4.0%	-6.5%	-6.48%
Assets 3Y	43.7%	46.9%	27.9%	18.4%	18.9%	19.0%	16.3%	5.9%	-0.3%	-1.8%	-3.3%	-13.8%	-19.0%	-19.3%	-12.8%	-7.0%	-7.0%	-7.8%	-10.5%	-5.1%	-5.06%
Assets 5Y	37.8%	35.8%	29.5%	25.1%	23.6%	25.9%	17.1%	13.4%	12.1%	17.0%	12.9%	4.8%	8.1%	3.2%	1.9%	0.2%	-4.2%	-4.0%	-6.8%	-7.5%	-7.47%
Equity 3Y	46.3%	50.4%	27.9%	17.6%	18.1%	18.7%	15.8%	4.7%	-1.6%	-4.0%	-5.2%	-16.4%	-21.3%	-21.7%	-13.1%	-7.2%	-7.3%	-8.1%	-11.1%	-5.3%	-5.30%
Book Value 3Y	46.4%	50.4%	28.2%	18.1%	18.2%	19.2%	16.3%	5.6%	-0.6%	-2.5%	-3.4%	-14.7%	-19.2%	-19.9%	-11.1%	-4.4%	-4.2%	-5.1%	-8.2%	-2.4%	-2.40%
Dividend 3Y	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—

Growth Quality

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Revenue Stability	0.73	0.87	0.89	0.82	0.78	0.86	0.82	0.64	0.53	0.54	0.37	0.18	0.12	0.11	0.07	0.10	0.08	0.01	0.50	0.80	0.800
Earnings Stability	0.74	0.89	0.13	0.00	0.02	0.01	0.02	0.13	0.09	0.14	0.19	0.34	0.14	0.44	0.65	0.30	0.21	0.27	0.45	0.11	0.113
Margin Stability	0.98	0.98	0.98	0.98	0.98	0.98	0.98	0.98	0.97	0.97	0.97	0.97	0.97	0.98	0.97	0.97	0.97	0.96	0.97	0.97	0.967
Rev. Growth Consistency	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.500
Earn. Growth Consistency	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.00	0.00	0.00	0.00	0.00	0.50	0.50	0.50	0.50	0.00	0.000
FCF Positive Streak	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
Earnings Persistence	0.50	0.95	0.20	0.20	0.20	0.20	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.50	0.20	0.95	0.20	0.20	0.50	0.500
Earnings Smoothness	0.38	0.89	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0.64	0.643
ROE Trend	0.20	-0.04	-0.33	-0.52	-1.13	-0.72	-0.21	-0.12	0.12	-0.04	-0.02	-0.06	0.26	-0.06	-0.30	0.17	-0.04	0.28	0.20	0.11	0.106
Gross Margin Trend	0.02	0.01	0.01	0.02	0.00	-0.00	-0.01	-0.03	-0.03	-0.03	-0.03	-0.02	-0.00	-0.01	-0.01	-0.01	-0.02	-0.02	-0.02	-0.01	-0.015
FCF Margin Trend	0.09	0.01	-0.02	-0.05	-0.14	-0.16	-0.13	-0.11	-0.06	-0.02	-0.03	-0.02	0.02	0.05	0.07	0.07	0.05	0.05	0.04	0.03	0.034
Sustainable Growth Rate	55.1%	36.0%	—	—	—	—	—	—	—	—	—	—	—	—	—	4.6%	—	10.8%	2.0%	2.4%	2.42%
Internal Growth Rate	71.4%	38.1%	—	—	—	—	—	—	—	—	—	—	—	—	—	3.3%	—	8.3%	1.4%	1.7%	1.72%

Cash Flow Quality

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
OCF/Net Income	0.12	0.15	-6.00	-0.25	-0.05	-0.06	-1.34	-0.70	-2.50	-0.59	-1.08	-0.26	-0.53	-0.25	-0.24	1.67	-0.73	0.70	3.02	2.21	2.215
FCF/OCF	0.85	0.82	0.77	0.74	0.56	0.39	0.50	0.51	0.58	0.58	0.54	0.51	0.54	0.58	0.64	0.65	0.69	0.70	0.70	0.72	0.717
FCF/Net Income	snapshot only																				1.588
OCF/EBITDA	snapshot only																				0.483
CapEx/Revenue	3.9%	4.1%	4.6%	4.5%	4.3%	4.5%	4.6%	5.2%	5.9%	5.9%	6.2%	6.6%	7.3%	7.4%	7.2%	7.3%	6.0%	6.1%	5.9%	5.4%	5.39%
CapEx/Depreciation	snapshot only																				0.946
Accruals Ratio	0.37	0.23	-0.05	-0.17	-0.39	-0.24	-0.03	-0.06	-0.04	-0.08	-0.05	-0.15	-0.11	-0.21	-0.24	-0.02	-0.12	0.02	-0.04	-0.03	-0.026
Sloan Accruals	snapshot only																				-0.034
Cash Flow Adequacy	snapshot only																				2.613
Earnings Quality Score	snapshot only																				1.000

Dividends & Buybacks

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	0.6%	0.00%
Dividend/Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$1.24	$1.83	$0.00
Payout Ratio	0.0%	0.0%	—	—	—	—	—	—	—	—	—	—	—	—	—	0.0%	—	0.0%	19.7%	22.0%	22.03%
FCF Payout Ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	9.3%	13.9%	13.88%
Total Payout Ratio	0.8%	1.2%	—	—	—	—	—	—	—	—	—	—	—	—	—	1.1%	—	38.9%	1.6%	81.7%	81.70%
Div. Increase Streak	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	0	0	0
Chowder Number	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Buyback Yield	0.2%	0.2%	0.0%	0.9%	1.0%	1.8%	1.6%	2.7%	3.1%	4.6%	4.6%	4.1%	4.4%	2.2%	4.4%	5.0%	3.9%	3.5%	3.2%	1.7%	1.67%
Net Buyback Yield	0.2%	0.2%	0.0%	0.9%	1.0%	1.8%	1.6%	2.7%	3.1%	4.6%	4.6%	4.1%	4.4%	2.2%	4.4%	4.9%	3.8%	3.4%	3.0%	0.6%	0.58%
Total Shareholder Return	0.2%	0.2%	0.0%	0.9%	1.0%	1.8%	1.6%	2.7%	3.1%	4.6%	4.6%	4.1%	4.4%	2.2%	4.4%	4.9%	3.8%	3.4%	3.5%	1.2%	1.20%

DuPont Factors

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Tax Burden (NI/EBT)	0.78	0.78	0.44	0.74	0.77	0.77	0.74	0.79	0.82	0.75	0.73	0.77	0.77	0.79	0.79	0.71	0.80	0.76	0.76	0.63	0.635
Interest Burden (EBT/EBIT)	1.00	1.00	1.02	1.01	1.00	1.01	1.25	1.10	1.35	1.06	1.13	1.03	1.05	1.02	1.02	0.90	2.73	0.65	0.29	0.40	0.402
EBIT Margin	2.87	1.86	-0.08	-0.90	-2.78	-1.67	-0.07	-0.17	-0.05	-0.30	-0.15	-0.66	-0.37	-0.89	-1.06	0.20	-0.12	0.59	0.29	0.34	0.337
Asset Turnover	0.19	0.19	0.20	0.21	0.18	0.18	0.20	0.22	0.23	0.21	0.20	0.24	0.23	0.24	0.23	0.26	0.25	0.26	0.27	0.25	0.253
Equity Multiplier	1.32	1.31	1.36	1.35	1.35	1.34	1.41	1.42	1.42	1.41	1.40	1.42	1.41	1.41	1.41	1.43	1.43	1.42	1.43	1.43	1.431

Per Share

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
EPS (Diluted TTM)	$220.31	$141.90	$-3.30	$-65.12	$-202.89	$-121.69	$-6.35	$-14.44	$-5.25	$-22.12	$-11.30	$-46.68	$-27.83	$-65.87	$-77.41	$11.72	$-25.10	$28.13	$6.26	$8.29	$8.29
Book Value/Share	$507.29	$457.36	$340.19	$299.48	$284.32	$322.75	$328.23	$287.75	$288.00	$303.36	$317.17	$238.73	$267.57	$234.64	$238.93	$261.82	$250.22	$275.94	$254.15	$267.54	$268.22
Tangible Book/Share	$491.77	$437.27	$320.39	$279.77	$259.94	$297.95	$303.50	$262.53	$263.32	$277.88	$291.72	$213.40	$241.75	$209.49	$213.51	$225.88	$214.30	$248.02	$226.55	$240.16	$240.16
Revenue/Share	$98.58	$97.67	$96.74	$96.36	$94.33	$94.06	$93.42	$94.33	$93.09	$92.70	$91.29	$90.25	$92.20	$91.67	$90.90	$93.81	$94.99	$95.63	$96.07	$96.57	$96.81
FCF/Share	$22.06	$17.90	$15.34	$12.21	$5.09	$2.70	$4.21	$5.20	$7.63	$7.57	$6.50	$6.25	$8.00	$9.51	$11.88	$12.76	$12.51	$13.87	$13.25	$13.17	$13.20
OCF/Share	$25.92	$21.94	$19.82	$16.52	$9.17	$6.89	$8.50	$10.14	$13.15	$13.01	$12.15	$12.19	$14.73	$16.26	$18.43	$19.62	$18.25	$19.70	$18.93	$18.37	$18.42
Cash/Share	$44.24	$29.07	$69.27	$66.04	$62.22	$60.11	$62.24	$58.68	$60.19	$55.77	$57.67	$56.92	$57.98	$59.45	$59.40	$50.46	$52.77	$57.11	$58.04	$60.36	$60.51
EBITDA/Share	$288.72	$187.25	$-2.27	$-81.83	$-257.81	$-151.33	$-1.18	$-10.08	$2.15	$-20.70	$-6.59	$-52.29	$-27.14	$-75.04	$-90.09	$25.20	$-4.31	$63.86	$35.42	$38.03	$38.03
Debt/Share	$7.80	$7.47	$46.91	$46.71	$46.38	$46.59	$46.45	$47.09	$48.09	$48.78	$49.05	$49.05	$49.60	$49.10	$48.99	$51.66	$51.83	$56.68	$51.12	$44.89	$44.89
Net Debt/Share	$-36.44	$-21.61	$-22.36	$-19.33	$-15.85	$-13.51	$-15.79	$-11.60	$-12.10	$-7.00	$-8.62	$-7.87	$-8.37	$-10.35	$-10.41	$1.20	$-0.94	$-0.43	$-6.92	$-15.47	$-15.47

Academic Models

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Altman Z-Score	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	3.419
Altman Z-Prime	snapshot only																				7.152
Piotroski F-Score	6	4	6	6	5	5	4	5	5	5	4	6	6	5	4	6	5	5	7	7	7
Beneish M-Score	-0.88	-1.38	-2.60	-3.39	-5.15	-3.81	-2.58	-2.66	-2.62	-2.92	-2.86	-3.52	-3.07	-3.83	-3.99	-2.47	-3.04	-2.25	-2.62	-2.67	-2.670
Ohlson O-Score	snapshot only																				-9.405
ROIC (Greenblatt)	snapshot only																				31.94%
Net-Net WC	snapshot only																				$-2.15
EVA	snapshot only																				$-526754748.86

Credit

Metric	Q3'21	Q4'21	Q1'22	Q2'22	Q3'22	Q4'22	Q1'23	Q2'23	Q3'23	Q4'23	Q1'24	Q2'24	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26	Current
Credit Rating	snapshot only																				AA+
Credit Score	97.75	97.75	70.50	66.00	49.50	54.00	66.60	64.50	56.10	60.60	64.50	60.00	65.10	60.60	57.00	85.50	66.00	94.00	88.25	90.10	90.100
Credit Grade	snapshot only																				2
Credit Trend	snapshot only																				4.600
Implied Spread (bps)	snapshot only																				65.000

BIO-B NYSE

Analyst Insights

Financial Rating

InsiderStreet Scorecard

Risk & Quality Signals

Valuation

DuPont Decomposition (5-Factor)

Graham-Dodd Adjusted Valuation

Profitability Trends

Leverage & Solvency Trends

Efficiency & Working Capital Trends

Growth Trends (YoY %)

Earnings Stability

Monte Carlo Price Simulation

Executive Compensation

C-Suite Compensation

CEO Pay Ratio

C-Suite Pay Equality (Gini)

CEO Compensation Mix

Workforce & Productivity

Scaling Efficiency

Sign in to InsiderStreet